A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include both indirect effects of metabolic improvement...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-09-01
|
| Series: | Kidney & Blood Pressure Research |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/534174 |
| _version_ | 1827794744638439424 |
|---|---|
| author | Jinfang Song Xia Li Jiang Ni |
| author_facet | Jinfang Song Xia Li Jiang Ni |
| author_sort | Jinfang Song |
| collection | DOAJ |
| description | Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include both indirect effects of metabolic improvement and direct effects, independent of glucose-lowering effects. Summary: In patients with diabetic kidney disease (DKD), several studies have demonstrated the potential nephroprotective mechanisms of SGLT2 inhibitors, and evidence of nephroprotective mechanisms in the non-DKD population is accumulating. Although the nephroprotective mechanism of SGLT2 inhibitors has not been fully elucidated, several laboratory studies have illustrated the mechanism underlying the effects of SGLT2 inhibitors at various aspects. Key Messages: The purpose of this article is to review the mechanism of nephroprotective effect of SGLT2 inhibitors and to look forward to promising research in the future. |
| first_indexed | 2024-03-11T18:38:14Z |
| format | Article |
| id | doaj.art-d184049a9c15448193e98bc695a7d086 |
| institution | Directory Open Access Journal |
| issn | 1423-0143 |
| language | English |
| last_indexed | 2024-03-11T18:38:14Z |
| publishDate | 2023-09-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney & Blood Pressure Research |
| spelling | doaj.art-d184049a9c15448193e98bc695a7d0862023-10-12T14:38:28ZengKarger PublishersKidney & Blood Pressure Research1423-01432023-09-011110.1159/000534174534174A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini ReviewJinfang Song0Xia Li1Jiang Ni2Department of Clinical Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, ChinaDepartment of Clinical Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, ChinaDepartment of Clinical Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, ChinaBackground: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include both indirect effects of metabolic improvement and direct effects, independent of glucose-lowering effects. Summary: In patients with diabetic kidney disease (DKD), several studies have demonstrated the potential nephroprotective mechanisms of SGLT2 inhibitors, and evidence of nephroprotective mechanisms in the non-DKD population is accumulating. Although the nephroprotective mechanism of SGLT2 inhibitors has not been fully elucidated, several laboratory studies have illustrated the mechanism underlying the effects of SGLT2 inhibitors at various aspects. Key Messages: The purpose of this article is to review the mechanism of nephroprotective effect of SGLT2 inhibitors and to look forward to promising research in the future.https://beta.karger.com/Article/FullText/534174sglt2 inhibitordiabetic kidney diseasenon-diabetic kidney diseasechronic kidney disease |
| spellingShingle | Jinfang Song Xia Li Jiang Ni A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review Kidney & Blood Pressure Research sglt2 inhibitor diabetic kidney disease non-diabetic kidney disease chronic kidney disease |
| title | A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review |
| title_full | A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review |
| title_fullStr | A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review |
| title_full_unstemmed | A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review |
| title_short | A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review |
| title_sort | role for sodium glucose cotransporter 2 inhibitors in the treatment of chronic kidney disease a mini review |
| topic | sglt2 inhibitor diabetic kidney disease non-diabetic kidney disease chronic kidney disease |
| url | https://beta.karger.com/Article/FullText/534174 |
| work_keys_str_mv | AT jinfangsong aroleforsodiumglucosecotransporter2inhibitorsinthetreatmentofchronickidneydiseaseaminireview AT xiali aroleforsodiumglucosecotransporter2inhibitorsinthetreatmentofchronickidneydiseaseaminireview AT jiangni aroleforsodiumglucosecotransporter2inhibitorsinthetreatmentofchronickidneydiseaseaminireview AT jinfangsong roleforsodiumglucosecotransporter2inhibitorsinthetreatmentofchronickidneydiseaseaminireview AT xiali roleforsodiumglucosecotransporter2inhibitorsinthetreatmentofchronickidneydiseaseaminireview AT jiangni roleforsodiumglucosecotransporter2inhibitorsinthetreatmentofchronickidneydiseaseaminireview |